CordenPharma is investing €80 million to expand aseptic fill-finish operations at its Caponago site in Italy, increasing projected sterile injectable capacity to up to 500 million units annually.

The acquisition makes Yapan Bio a Piramal Pharma subsidiary, strengthening the company's integrated biologics development and manufacturing offering for vaccines, biologics and antibody-drug conjugates.

The long-term manufacturing agreement covers 55 oncology and non-oncology products across three Gland Pharma sites, with commercial revenue expected to begin in 2029.